Literature DB >> 23724389

Pulmonary embolism.

Abigail K Tarbox1, Mamta Swaroop.   

Abstract

Pulmonary embolism (PE) is responsible for approximately 100,000 to 200,000 deaths in the United States each year. With a diverse range of clinical presentations from asymptomatic to death, diagnosing PE can be challenging. Various resources are available, such as clinical scoring systems, laboratory data, and imaging studies which help guide clinicians in their work-up of PE. Prompt recognition and treatment are essential for minimizing the mortality and morbidity associated with PE. Advances in recognition and treatment have also enabled treatment of some patients in the home setting and limited the amount of time spent in the hospital. This article will review the risk factors, pathophysiology, clinical presentation, evaluation, and treatment of PE.

Entities:  

Keywords:  Pulmonary embolism; thrombosis; venous thromboembolism

Year:  2013        PMID: 23724389      PMCID: PMC3665123          DOI: 10.4103/2229-5151.109427

Source DB:  PubMed          Journal:  Int J Crit Illn Inj Sci        ISSN: 2229-5151


INTRODUCTION

Venous thromboembolism (VTE) and PE is the third most common cause of cardiovascular death after myocardial infarction (MI) and cerebrovascular accidents (CVA).[1] Many PEs are likely undiagnosed and calculating the true incidence remains challenging. However, PE remains a significant cause of preventable in-hospital mortality.

RISK FACTORS

Most clinically significant PEs originate as VTEs in the lower extremities or pelvic veins. Less frequently, upper extremity thromboembolic events lead to PE. Various conditions lead to the generation of VTE. Virchow's triad of hypercoagulability, venous stasis, and vessel wall injury provides a model for understanding many of the risk factors. These factors are usually either inherited or acquired, as shown in Tables 1 and 2. Overall, major risk factors for thromboembolic events include recent immobilization, MI, CVA, surgery, and recent trauma. Additional major risk factors include prior VTE, advanced age, malignancy, known thrombophilia, and indwelling venous catheter. Moderate risk factors include family history of VTE, use of estrogen or hormone replacement therapy, smoking, pregnancy, and obesity.
Table 1

Inherited Risk Factors for VTE[23]

Table 2

Acquired Risk Factors for VTE[2–4]

Inherited Risk Factors for VTE[23] Acquired Risk Factors for VTE[2-4]

PATHOPHYSIOLOGY

PE occurs when deep venous thrombi detach and embolize to the pulmonary circulation. Pulmonary vascular occlusion occurs and impairs gas exchange and circulation. In the lungs, the lower lobes are more frequently affected than the upper, with bilateral lung involvement being common. Larger emboli wedge in the main pulmonary artery, while smaller emboli occlude the peripheral arteries. Peripheral PE can lead to pulmonary infarction, manifested by intra-alveolar hemorrhage. Pulmonary infarction occurs in about 10% of patients without underlying cardiopulmonary disease. Obstruction of the pulmonary arteries creates dead space ventilation as alveolar ventilation exceeds pulmonary capillary blood flow. This contributes to ventilation-perfusion mismatch, with vascular occlusion of the arteries increasing pulmonary vascular resistance. In addition, humoral mediators, such as serotonin and thromboxane, are released from activated platelets and may trigger vasoconstriction in unaffected areas of lung. As the pulmonary artery systolic pressure increases, right ventricular after load increases, leading to right ventricular failure. As the right ventricular failure progresses, impairment in left ventricular filling may develop. Rapid progression to myocardial ischemia may occur secondary to inadequate coronary artery filling, with potential for hypotension, syncope, electromechanical dissociation, or sudden death.

CLINICAL PRESENTATION

Prompt recognition of a PE is crucial because of the high associated mortality and morbidity, which may be prevented with early treatment. Failure to diagnose PE is a serious management error since 30% of untreated patients die, while only 8% succumb with effective therapy.[5] Unfortunately, PE may be asymptomatic or present with sudden death. Characteristic signs and symptoms such as tachycardia, dyspnea, chest pain, hypoxemia, and shock are non-specific and are present in many other conditions, such as acute MI, congestive heart failure, or pneumonia. In the Prospective Investigation of Pulmonary Embolism Diagnosis II (PIOPED II) trial, patients with PE had a range of signs and symptoms. Common signs were tachypnea (54%) and tachycardia (24%). The most common symptoms were dyspnea, usually of onset within seconds, at rest or with exertion (73%), pleuritic pain (44%), calf or thigh pain (44%), calf or thigh swelling (41%), and cough (34%).[6] With only 24% of patients presenting with tachycardia, the majority of patients lacked one of the most common findings. Additionally, PIOPED II excluded many types of patients, such as those with chronic elevated creatinine levels or receiving dialysis, critically ill patients, or people with recent MI. Applicability is therefore limited. Therefore, a high index of suspicion and assessment of risk factors are critical for the recognition of pulmonary embolic events.

EVALUATION

Because of the variable nature of the presentation of PE, the evaluation largely depends on the likelihood of PE and the stability of the patient. There are scoring systems to assist in the determination of likelihood of PE and thromboembolic events. Diagnostic scoring systems such as the Wells criteria and Geneva score are often used [Tables 3 and 4].
Table 3

Modified Wells Criteria

Table 4

Revised Geneva Score

Modified Wells Criteria Revised Geneva Score Beyond the Wells and Geneva systems, which clinicians use to help rule in thrombosis, the PE Rule-Out Criteria (PERC) can help rule-out PE in low-risk emergency department patients. PERC criteria are listed in Table 5.
Table 5

PE Rule-out Criteria[9]

PE Rule-out Criteria[9] If a patient fulfills all of the PERC criteria and has a low probability of PE by Wells criteria and the gestalt opinion of the evaluating physician, then a PE may be ruled out.[9] In reality, very few patients meet these criteria and the PERC assessment is not reliable for the in-hospital setting. The aforementioned tools: Wells score, Geneva score, and PERC work best in assessing the need for further work-up of stable patients presenting to the emergency room; with inpatients and critically ill patients, such tools are not as reliable. The elements of diagnostic workup will vary depending on whether the patient is hospitalized and whether there is hemodynamic instability. In a patient with a suspected PE, diagnosis of proximal DVT in a symptomatic patient, or in an asymptomatic patient who has contraindications to CT angiography, is sufficient to rule in PE.[10] In a stable patient, presenting from an outpatient setting, who has not sustained recent trauma or surgery, a d-dimer test should be performed. If negative, and clinical suspicion is low, then the likelihood of PE is low and further workup is unnecessary. d-Dimer is a degradation product of cross-linked fibrin that is formed immediately after fibrin clots are degraded by plasmin and reflects a global activation of blood coagulation and fibrinolysis. Therefore, d-dimer is not a useful test in post-operative patients because it will be elevated due to coagulation and fibrinolysis. It is also elevated in trauma patients, hospitalized patients, and those with critical illness for similar reasons. Extremity venous ultrasound (US) is a quick, noninvasive modality that can detect DVT. Because it can be performed with a portable machine, venous US may negate the need for potentially dangerous transport of unstable, critically ill patients. Unfortunately, US testing often depends on the availability of technicians to perform the imaging and further evaluation by radiologists and other physicians with such skills. Recently, emergency room physicians and intensivists have been trained in US which results in faster detection of both symptomatic and asymptomatic extremity thromboses. When performed by trained ICU physicians, compression US studies of the extremities yielded a sensitivity of 86% and a specificity of 96% with a diagnostic accuracy of 95%.[11] In this same trial, median time delay between the ordering of formal vascular study (FVS) and the FVS result was 13.8 hours, which leads to significant delays in treatment. In another study, after 10 minutes of training in two point compression ultrasound, emergency medicine physicians were able to detect lower extremity thrombosis with a sensitivity of 100% and a specificity of 99%.[12] Besides the limitations of time delays due to lack of available personnel to perform such imaging, there are certain patient limitations that may limit study accuracy and feasibility; obesity, edema, and dressings often impede good imaging quality.[13] The other consideration in obtaining lower extremity ultrasound for diagnosis of PE is that it is not a reliable modality to check for pelvic venous thrombosis and there are also many instances in which patients have PEs, but no evidence of extremity thrombosis. In one study, the use of ultrasonography alone for suspected PE had a sensitivity of only 29%.[14] Furthermore, false positive results may result in potentially dangerous and unnecessary anticoagulation in patients who do not actually have PEs. Helical CT angiography has largely replaced ventilation-perfusion (V/Q) lung scanning for diagnosis because it is rapid, permits direct visualization of PE, and can demonstrate other diagnoses in patients without PE. In patients with a contraindication to intravenous contrast dye, a V/Q scan is used. A normal lung scan effectively excludes the diagnosis of PE, but only 25% of patients with suspected PE have a normal scan. In one of the largest studies evaluating V/Q scanning, the PIOPED II trial, V/Q scans could effectively rule-out PE in patients with a very low probability scan and a very low clinical likelihood of PE.[15] Other additional tests such as EKG or echocardiography may help with the diagnosis. However, EKG findings are often non-specific, as tachycardia is frequent. Evidence of right heart strain on EKG or echocardiography may support the diagnosis as well as provide information about the severity of the PE. One particular finding on echocardiogram, known as the McConnell's sign, is strongly suggestive of PE. In those patients with suspected PE and right ventricular dysfunction, the finding of normal wall motion of the RV apex but akinesia of the mid-RV free wall has a positive predictive value of 71% for the diagnosis of PE and a negative predictive value of 96%.[16]

TREATMENT

In hemodynamically stable patients, without contraindications to systemic anticoagulation, parenteral anticoagulation with subsequent conversion to vitamin K antagonists is the mainstay of therapy. Early initiation is paramount as patients may quickly decompensate. Patients who present to the emergency room with acute PE have decreased mortality if anticoagulation treatment commences in the emergency room, rather than waiting until after admission.[17] Supportive care of hypoxemia and hemodynamic instability should be instituted. Hemodynamically unstable patients may benefit from fibrinolytic therapy. However, the role for fibrinolysis is limited, with significant bleeding occurring in up to 13% of patients. The use of bolus thrombolytics during cardiopulmonary arrest may have some benefit when PE is strongly suspected[1819] and the patient does not respond to resuscitation. Mechanical thrombolysis with catheter-directed embolectomy and fibrinolytic therapy can also be used. Systemic heparin, either in the form of unfractionated heparin or low-molecular-weight heparin (LMWH), is the mainstay of treatment. LMWH is advantageous in ease of administration, monitoring, lower potential for heparin-induced thrombocytopenia. However, it is not an appropriate choice for patients with renal failure or for patients at significant risk of bleeding, because of its longer half-life and lack of reversibility. Newer options for anticoagulation include oral factor Xa inhibition with agents under investigation, such as rivaroxaban.[2021] If patients continue to have PEs despite therapeutic anticoagulation, experience bleeding events, or have other contraindications to anticoagulation, permanent or temporary inferior vena cava filters (IVCF) may be used. IVCF can prevent further pulmonary emboli in patients with lower extremity deep venous thrombosis, but do not reduce mortality. Propagating iliofemoral venous thrombus while on anticoagulation is another indication for IVCF placement.

SUMMARY

VTE and PE remain preventable causes of morbidity and mortality. By combining patient presentation, clinical suspicion, and scoring systems, diagnosis may be streamlined and unnecessary treatment may be minimized. More physicians have training and access to portable ultrasound devices, which may prevent delays in recognition and treatment of VTE. In-hospital patients, especially those who are critically ill, continue to pose diagnostic dilemmas. In such patients, clinical scoring systems and imaging may be inconclusive. The improved accuracy of helical CT scans has improved our recognition of PE in many of these patients.
  19 in total

1.  The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society.

Authors:  V F Tapson; B A Carroll; B L Davidson; C G Elliott; P F Fedullo; C A Hales; R D Hull; T M Hyers; K V Leeper; T A Morris; K M Moser; G E Raskob; D Shure; H D Sostman; B Taylor Thompson
Journal:  Am J Respir Crit Care Med       Date:  1999-09       Impact factor: 21.405

2.  Accuracy of ultrasonography performed by critical care physicians for the diagnosis of DVT.

Authors:  Pierre D Kory; Crescens M Pellecchia; Ariel L Shiloh; Paul H Mayo; Christopher DiBello; Seth Koenig
Journal:  Chest       Date:  2010-10-28       Impact factor: 9.410

3.  Successful outcome of cardiopulmonary arrest with systemic thrombolysis.

Authors:  Julio Flores; J García de Tena; Raúl de Pablo; Martín Daguerre
Journal:  Eur J Intern Med       Date:  2008-04-14       Impact factor: 4.487

Review 4.  Deep vein thrombosis--risks and diagnosis.

Authors:  Wai Khoon Ho
Journal:  Aust Fam Physician       Date:  2010-07

5.  Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.

Authors:  P S Wells; D R Anderson; M Rodger; J S Ginsberg; C Kearon; M Gent; A G Turpie; J Bormanis; J Weitz; M Chamberlain; D Bowie; D Barnes; J Hirsh
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

6.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

Review 7.  Pulmonary embolism and deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Henri Bounameaux
Journal:  Lancet       Date:  2012-04-10       Impact factor: 79.321

8.  Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.

Authors:  Sean B Smith; Jeffrey B Geske; Jennifer M Maguire; Nicholas A Zane; Rickey E Carter; Timothy I Morgenthaler
Journal:  Chest       Date:  2010-01-15       Impact factor: 9.410

9.  Very low probability interpretation of V/Q lung scans in combination with low probability objective clinical assessment reliably excludes pulmonary embolism: data from PIOPED II.

Authors:  Alexander Gottschalk; Paul D Stein; H Dirk Sostman; Fadi Matta; Afzal Beemath
Journal:  J Nucl Med       Date:  2007-09       Impact factor: 10.057

10.  Venous thromboembolism: classification, risk factors, diagnosis, and management.

Authors:  Fatemeh Moheimani; Denise E Jackson
Journal:  ISRN Hematol       Date:  2011-10-17
View more
  15 in total

1.  Drug Targeting via Platelet Membrane-Coated Nanoparticles.

Authors:  Shuyan Wang; Yaou Duan; Qiangzhe Zhang; Anvita Komarla; Hua Gong; Weiwei Gao; Liangfang Zhang
Journal:  Small Struct       Date:  2020-09-09

2.  Effectiveness of high flow nasal cannula oxygen therapy in patients of acute pulmonary thromboembolism with acute hypoxemic respiratory failure.

Authors:  Vikas Marwah; P S Shafin Babu; C D S Katoch; Gaurav Bhati; Deepu K Peter
Journal:  Med J Armed Forces India       Date:  2021-05-26

3.  Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism.

Authors:  Li Wang; Onur Baser; Phil Wells; W Frank Peacock; Craig I Coleman; Gregory J Fermann; Jeff Schein; Concetta Crivera
Journal:  J Health Econ Outcomes Res       Date:  2019-04-08

4.  Sex differences in presentation, management, and outcomes among patients hospitalized with acute pulmonary embolism.

Authors:  Abby M Pribish; Sebastian E Beyer; Anna K Krawisz; Ido Weinberg; Brett J Carroll; Eric A Secemsky
Journal:  Vasc Med       Date:  2020-11-17       Impact factor: 3.239

5.  Pulmonary embolism as the initial presentation of testicular carcinoma.

Authors:  Ilhami Berber; Recep Bentli; Mehmet Ali Erkurt; Ozkan Ulutas; Caner Ediz; Ilknur Nizam; Nurcan Kırıcı Berber; Serkan Unlu; Reyhan Koroglu; Mustafa Koroglu; Nusret Akpolat
Journal:  Case Rep Oncol Med       Date:  2013-12-09

6.  Stress Hyperglycaemia Indicates Embolus Size and Localization in Patients with Acute Pulmonary Embolism.

Authors:  Velimir Altabas; Lucija Pukec; Stella Mlinarić; Hrvoje Pintarić; Aljoša Šikić
Journal:  Int J Endocrinol       Date:  2020-07-08       Impact factor: 3.257

7.  Lung Cancer Complicated With Asymptomatic Pulmonary Embolism: Clinical Analysis of 84 Patients.

Authors:  Guangsheng Li; Yuechuan Li; Shuping Ma
Journal:  Technol Cancer Res Treat       Date:  2017-11-01

8.  A rare case report of a saddle pulmonary embolism presenting with high grade fevers, responsive to anticoagulation.

Authors:  Muhammad Saad; Danial H Shaikh; Muhammad Adrish
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

9.  Benefit of early discharge among patients with low-risk pulmonary embolism.

Authors:  Li Wang; Onur Baser; Phil Wells; W Frank Peacock; Craig I Coleman; Gregory J Fermann; Jeff Schein; Concetta Crivera
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

10.  Recurrent Syncope as a Presentation of Pulmonary Embolism.

Authors:  Kulachanya Suwanwongse; Nehad Shabarek
Journal:  Cureus       Date:  2020-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.